AS
Altshuler Shaham Portfolio holdings
AUM
$3.14B
1-Year Return
24.55%
This Quarter Return
-1.75%
1 Year Return
+24.55%
3 Year Return
+51.84%
5 Year Return
+71.45%
10 Year Return
–
AUM
$2.6B
AUM Growth
+$216M
(+9.1%)
Cap. Flow
+$270M
Cap. Flow
% of AUM
10.4%
Top 10 Holdings %
Top 10 Hldgs %
80.17%
Holding
604
New
246
Increased
175
Reduced
83
Closed
81
Top Buys
| 1 |
WIX.com
WIX
|
+$75.5M |
| 2 |
Financial Select Sector SPDR Fund
XLF
|
+$64.5M |
| 3 |
Cisco
CSCO
|
+$45.4M |
| 4 |
iShares MSCI South Korea ETF
EWY
|
+$37.6M |
| 5 |
Check Point Software Technologies
CHKP
|
+$28.4M |
Top Sells
| 1 |
GZT
Gazit-globe Ltd
GZT
|
+$91.7M |
| 2 |
LivePerson
LPSN
|
+$16.8M |
| 3 |
AudioCodes
AUDC
|
+$3.18M |
| 4 |
Allot
ALLT
|
+$2.13M |
| 5 |
United Parcel Service
UPS
|
+$1.77M |
Sector Composition
| 1 | Technology | 34.07% |
| 2 | Consumer Discretionary | 16.76% |
| 3 | Industrials | 8.26% |
| 4 | Financials | 1.19% |
| 5 | Healthcare | 1.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
276
Hologic
HOLX
$14.8B
| $10K | ﹤0.01% |
192
-34
| -15% | -$1.77K |
|
277
Henry Schein
HSIC
$8.2B
| $10K | ﹤0.01% |
153
| – | – |
|
278
HealthStream
HSTM
$850M
| $10K | ﹤0.01% |
+371
| New | +$10K |
|
279
The Joint Corp
JYNT
$163M
| $10K | ﹤0.01% |
+548
| New | +$10K |
|
280
LeMaitre Vascular
LMAT
$2.16B
| $10K | ﹤0.01% |
+296
| New | +$10K |
|
281
Mettler-Toledo International
MTD
$26.5B
| $10K | ﹤0.01% |
14
-33
| -70% | -$23.6K |
|
282
Vertex Pharmaceuticals
VRTX
$102B
| $10K | ﹤0.01% |
+60
| New | +$10K |
|
283
Dentsply Sirona
XRAY
$2.77B
| $10K | ﹤0.01% |
182
-323
| -64% | -$17.7K |
|
284
Abbott
ABT
$230B
| $9K | ﹤0.01% |
111
-20
| -15% | -$1.62K |
|
285
Addus HomeCare
ADUS
$2.08B
| $9K | ﹤0.01% |
+117
| New | +$9K |
|
|
AMED
286
DELISTED
Amedisys
AMED
| $9K | ﹤0.01% |
+71
| New | +$9K |
|
287
Amgen
AMGN
$151B
| $9K | ﹤0.01% |
+46
| New | +$9K |
|
288
Anika Therapeutics
ANIK
$126M
| $9K | ﹤0.01% |
+167
| New | +$9K |
|
289
Alphatec Holdings
ATEC
$2.34B
| $9K | ﹤0.01% |
+1,848
| New | +$9K |
|
290
Bio-Rad Laboratories Class A
BIO
$7.74B
| $9K | ﹤0.01% |
28
-7
| -20% | -$2.25K |
|
291
Boston Scientific
BSX
$160B
| $9K | ﹤0.01% |
222
-39
| -15% | -$1.58K |
|
292
Chemed
CHE
$6.74B
| $9K | ﹤0.01% |
22
-8
| -27% | -$3.27K |
|
293
Coherus Oncology, Inc. Common Stock
CHRS
$157M
| $9K | ﹤0.01% |
+429
| New | +$9K |
|
294
Cooper Companies
COO
$13.6B
| $9K | ﹤0.01% |
124
-8
| -6% | -$581 |
|
295
Haemonetics
HAE
$2.61B
| $9K | ﹤0.01% |
+72
| New | +$9K |
|
296
Huron Consulting
HURN
$2.42B
| $9K | ﹤0.01% |
+147
| New | +$9K |
|
297
Integra LifeSciences
IART
$1.2B
| $9K | ﹤0.01% |
+160
| New | +$9K |
|
298
Incyte
INCY
$16.7B
| $9K | ﹤0.01% |
124
-1
| -0.8% | -$73 |
|
299
IQVIA
IQV
$32.2B
| $9K | ﹤0.01% |
+62
| New | +$9K |
|
300
Johnson & Johnson
JNJ
$426B
| $9K | ﹤0.01% |
72
-4
| -5% | -$500 |
|